US FDA sets October date for review of Medtronic's Endeavor stent:
This article was originally published in Clinica
Executive Summary
A US FDA advisory panel is to review the premarket approval (PMA) application for Medtronic's Endeavor drug-eluting stent (DES) next month, the Minneapolis, Minnesota company revealed yesterday. The agency's Circulatory System Devices Panel is scheduled to meet on October 10-11, with Endeavor the only DES on the agenda for review during the meeting.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.